Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

1 Feb 2017

Abstract excerpt

BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced transcriptional response identified the immune checkpoint ligand Cd274 (Pd-l1) as a Myc-independent, BETi target-gene. BETi...

Topics

Join the communities discussing this publication.

CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28249162
DOI: 10.1016/j.celrep.2017.02.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1PMID 28249162Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infectionSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

BET bromodomain inhibition suppresses TH17-mediated pathologySemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Targeting MYC dependence in cancer by inhibiting BET bromodomainsSemantic proximity Read ↗

The Functions of BET Proteins in Gene Transcription of Biology and DiseasesSemantic proximity Read ↗

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.